Literature DB >> 31183991

Small-Molecule Activators of Glucose-6-phosphate Dehydrogenase (G6PD) Bridging the Dimer Interface.

Andrew G Raub1,2, Sunhee Hwang1, Naoki Horikoshi3,4,5, Anna D Cunningham1,6, Simin Rahighi4,5,7, Soichi Wakatsuki4,5, Daria Mochly-Rosen1.   

Abstract

We recently identified AG1, a small-molecule activator that functions by promoting oligomerization of glucose-6-phosphate dehydrogenase (G6PD) to the catalytically competent forms. Biochemical experiments indicate that the activation of G6PD by the original hit molecule (AG1) is noncovalent and that one C2 -symmetric region of the G6PD homodimer is important for ligand function. Consequently, the disulfide in AG1 is not required for activation of G6PD, and a number of analogues were prepared without this reactive moiety. Our study supports a mechanism of action whereby AG1 bridges the dimer interface at the structural nicotinamide adenine dinucleotide phosphate (NADP+ ) binding sites of two interacting G6PD monomers. Small molecules that promote G6PD oligomerization have the potential to provide a first-in-class treatment for G6PD deficiency. This general strategy could be applied to other enzyme deficiencies in which control of oligomerization can enhance enzymatic activity and/or stability.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  bivalent ligands; enzyme catalysis; glucose-6-phosphate dehydrogenase; protein-protein interactions; small-molecule activators

Mesh:

Substances:

Year:  2019        PMID: 31183991      PMCID: PMC6701841          DOI: 10.1002/cmdc.201900341

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  18 in total

Review 1.  The druggable genome.

Authors:  Andrew L Hopkins; Colin R Groom
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

2.  Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.

Authors:  Paul Hebeisen; Bernd Kuhn; Philipp Kohler; Marcel Gubler; Walter Huber; Eric Kitas; Brigitte Schott; Jörg Benz; Catherine Joseph; Armin Ruf
Journal:  Bioorg Med Chem Lett       Date:  2008-07-05       Impact factor: 2.823

3.  Turning enzymes ON with small molecules.

Authors:  Julie A Zorn; James A Wells
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

4.  Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency.

Authors:  S W Au; S Gover; V M Lam; M J Adams
Journal:  Structure       Date:  2000-03-15       Impact factor: 5.006

5.  Structure and function of glucose-6-phosphate dehydrogenase-deficient variants in Chinese population.

Authors:  Weiying Jiang; Guolong Yu; Peng Liu; Qian Geng; Luming Chen; Qundi Lin; Xiaoqin Ren; Wenhong Ye; Yongshu He; Yibin Guo; Shan Duan; Jing Wen; Haiyuan Li; Yan Qi; Chengrui Jiang; Yongmei Zheng; Chun Liu; En Si; Qin Zhang; Qiuhong Tian; Chuanshu Du
Journal:  Hum Genet       Date:  2006-04-11       Impact factor: 4.132

6.  Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.

Authors:  Che-Hong Chen; Grant R Budas; Eric N Churchill; Marie-Hélène Disatnik; Thomas D Hurley; Daria Mochly-Rosen
Journal:  Science       Date:  2008-09-12       Impact factor: 47.728

7.  Estimating the size of the human interactome.

Authors:  Michael P H Stumpf; Thomas Thorne; Eric de Silva; Ronald Stewart; Hyeong Jun An; Michael Lappe; Carsten Wiuf
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

Review 8.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  M D Cappellini; G Fiorelli
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

9.  Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant.

Authors:  Samantha Perez-Miller; Hina Younus; Ram Vanam; Che-Hong Chen; Daria Mochly-Rosen; Thomas D Hurley
Journal:  Nat Struct Mol Biol       Date:  2010-01-10       Impact factor: 15.369

10.  Discovery of selective small-molecule activators of a bacterial glycoside hydrolase.

Authors:  John F Darby; Jens Landström; Christian Roth; Yuan He; Gideon J Davies; Roderick E Hubbard
Journal:  Angew Chem Int Ed Engl       Date:  2014-10-07       Impact factor: 15.336

View more
  7 in total

Review 1.  Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.

Authors:  Adriana A Garcia; Ana Koperniku; Julio C B Ferreira; Daria Mochly-Rosen
Journal:  Trends Pharmacol Sci       Date:  2021-08-10       Impact factor: 17.638

2.  H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth.

Authors:  Chunwan Lu; Dafeng Yang; John D Klement; Yolonda L Colson; Nicholas H Oberlies; Cedric J Pearce; Aaron H Colby; Mark W Grinstaff; Zhuoqi Liu; Huidong Shi; Han-Fei Ding; Kebin Liu
Journal:  Oncogene       Date:  2022-03-30       Impact factor: 8.756

Review 3.  Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

Authors:  Kaitlyn Ryan; Babu L Tekwani
Journal:  Pharmacol Ther       Date:  2020-12-14       Impact factor: 13.400

4.  Discovery of Small-Molecule Activators for Glucose-6-Phosphate Dehydrogenase (G6PD) Using Machine Learning Approaches.

Authors:  Madhu Sudhana Saddala; Anton Lennikov; Hu Huang
Journal:  Int J Mol Sci       Date:  2020-02-23       Impact factor: 5.923

5.  Long-range structural defects by pathogenic mutations in most severe glucose-6-phosphate dehydrogenase deficiency.

Authors:  Naoki Horikoshi; Sunhee Hwang; Cornelius Gati; Tsutomu Matsui; Carlos Castillo-Orellana; Andrew G Raub; Adriana A Garcia; Fatemeh Jabbarpour; Alexander Batyuk; Joshua Broweleit; Xinyu Xiang; Andrew Chiang; Rachel Broweleit; Esteban Vöhringer-Martinez; Daria Mochly-Rosen; Soichi Wakatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

6.  Combined effects of double mutations on catalytic activity and structural stability contribute to clinical manifestations of glucose-6-phosphate dehydrogenase deficiency.

Authors:  Phonchanan Pakparnich; Sirapapha Sudsumrit; Mallika Imwong; Teeraporn Suteewong; Kamonwan Chamchoy; Danaya Pakotiprapha; Ubolsree Leartsakulpanich; Usa Boonyuen
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

Review 7.  Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.

Authors:  Dina Alramadhani; Anfal S Aljahdali; Osheiza Abdulmalik; B Daniel Pierce; Martin K Safo
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.